Q2 EPS Estimates for Traws Pharma Lifted by HC Wainwright

Traws Pharma, Inc. (NASDAQ:TRAW) – Stock analysts at HC Wainwright upped their Q2 2026 earnings estimates for shares of Traws Pharma in a research report issued on Thursday, June 18th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.22) per share for the quarter, up from their previous forecast of ($0.41). HC Wainwright currently has a “Negative” rating and a $1.00 target price on the stock. The consensus estimate for Traws Pharma’s current full-year earnings is ($1.43) per share. HC Wainwright also issued estimates for Traws Pharma’s Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at ($0.12) EPS, FY2026 earnings at ($1.01) EPS, FY2027 earnings at ($0.57) EPS, FY2028 earnings at ($0.56) EPS, FY2029 earnings at ($0.27) EPS and FY2030 earnings at $0.17 EPS.

A number of other equities research analysts also recently issued reports on TRAW. LADENBURG THALM/SH SH downgraded shares of Traws Pharma from a “buy” rating to a “neutral” rating in a research report on Monday, June 15th. Wall Street Zen raised Traws Pharma from a “strong sell” rating to a “sell” rating in a report on Saturday, June 13th. Citigroup downgraded Traws Pharma to a “neutral” rating in a research report on Monday, June 15th. Finally, Weiss Ratings lowered Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. Three equities research analysts have rated the stock with a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of “Reduce” and an average price target of $1.00.

Traws Pharma Stock Performance

Shares of TRAW stock opened at $0.85 on Monday. Traws Pharma has a 12 month low of $0.64 and a 12 month high of $3.27. The stock has a market cap of $8.64 million, a P/E ratio of -0.50 and a beta of 1.45. The company has a 50 day simple moving average of $1.41 and a two-hundred day simple moving average of $1.68.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings data on Friday, May 15th. The company reported ($0.53) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.39.

Hedge Funds Weigh In On Traws Pharma

Several large investors have recently made changes to their positions in the business. Two Sigma Investments LP raised its stake in Traws Pharma by 37.1% during the 3rd quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after purchasing an additional 5,955 shares during the period. Geode Capital Management LLC boosted its stake in Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock worth $70,000 after purchasing an additional 18,213 shares during the period. State Street Corp bought a new position in Traws Pharma in the 4th quarter worth approximately $29,000. XTX Topco Ltd grew its holdings in Traws Pharma by 294.2% during the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock valued at $48,000 after buying an additional 31,502 shares in the last quarter. Finally, Seven Fleet Capital Management LP purchased a new stake in Traws Pharma during the 4th quarter valued at approximately $56,000. 7.95% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Traws Pharma news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the business’s stock in a transaction on Thursday, April 16th. The stock was acquired at an average price of $1.67 per share, for a total transaction of $998,207.43. Following the purchase, the insider owned 1,203,250 shares of the company’s stock, valued at approximately $2,009,427.50. This represents a 98.71% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 7.57% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.